공고 • Jun 15
Zelira Therapeutics Limited announced that it expects to receive $0.1 million in funding Zelira Therapeutics Limited has announced a private placement of 20% Unsecured Convertible Loan Note for gross proceeds of $100,000 on June 15, 2026. The loan note will be convertible into shares at the conversion price of $0.2812 per share. This represents an over 20% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Osagie Imasogie and who is the Non-Executive Chairman. The interest payment is 20% per annum paid monthly in cash and the maturity date is June 15, 2027. The company announced that it has obtained approval from board of directors and subject to the approval of shareholders. 공고 • Mar 10
Zelira Therapeutics Limited announced that it expects to receive AUD 0.05 million in funding Zelira Therapeutics Limited has announced a private placement of Loan Note for AUD 50,000 on March 10, 2026. The loan note will be convertible into shares at the higher of AUD 0.58 conversion price. This represents an over 14.7% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Mr Tim Slate and who is the Non-exicutive Director. The interest payment is 20% per annum paid monthly in cash and the maturity date is March 10, 2027.The transaction is subject to the approval of shareholders. 공고 • Sep 24
Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025 Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025. 공고 • Sep 17
Zelira Therapeutics Limited announced that it expects to receive $0.15 million in funding Zelira Therapeutics Limited has announced a private placement on September 16, 2025, of USD 150,000 of loan note which will become convertible into shares at the higher of USD$0.2585 and the 15-day VWAP prior Zelira electing to convert. The Loan Notes are are being executed by Oludare Odumosu and r Donna Gentile O’Donnell of f USD$100,000 and USD$50,000 respectively, on attractive terms. The interest payment is 20% per annum paid monthly in cash and the maturity date is September 16, 2026. 공고 • Sep 12
Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024 Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024. 공고 • Jul 05
Zelira Therapeutics Limited announced that it has received $1.4 million in funding On July 4, 2024, Zelira Therapeutics Limited closed the transaction. 공고 • Sep 15
Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023 Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023. Agenda: To consider the re-election of Directors. 공고 • May 31
Zelira Therapeutics Limited Announces Board Changes Zelira Therapeutics Ltd. announced it has appointed Dr. Donna Gentile O'Donnell as non-executive director, effective 1 June 2023. Dr. O'Donnell served as Special Assistant to the President, Dr. Stephen K. Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years. There, she played a significant role in developing and creating BioAdvance, a state entity designed to grow the life sciences industry in Southeastern Pennsylvania, as well as many other key life science initiatives. She was a special limited partner in PA Early Stage Partners. As former president of Franklin Health Trust, Dr. O'Donnell was instrumental in leading the negotiations for the merger of $50 million of the foundation's assets into the Drexel University College of Medicine. She served as Deputy Health Commissioner for Policy and Planning in the City of Philadelphia in the mid-1990s under former Mayor Ed Rendell. During that time she wrote the only successful competitive federal health care grant in the Summer of Service program, to increase the rate of immunisation for at-risk children, newborn to 2 years old and received the Clara Barton Humanitarian Award from the Southeastern Pennsylvania Chapter of the American Red Cross. In 2020, she was elected as a Fellow to the Philadelphia College of Physicians. In 2005, she was awarded Philadelphia Business Journal's Women of Distinction Award. In 2017, Gov. Tom Wolf appointed her to the Health Research Advisory Committee, which oversees the Commonwealth Universal Research Enhancement Program, or CURE. The CURE program, administered by the Pennsylvania Department of Health, advises on the distribution of 19% of the $11 billion tobacco settlement that goes to health and life-science-related research. In addition, Dr. O'Donnell served on the Women's Financial Services Network Advisory Board for PNC Bank and has served on the Regional Editorial Board of ADVANCE For Nurses. Furthermore, the company that Ms. Lisa Gray has resigned from the position of Non-Executive Director effective 31 May 2023, to focus on her other business interests and directorships. The board is wholeheartedly grateful to Ms. Gray for her significant contribution to the company as one of its founding Directors and wish her all the best with her future endeavours. Ms. Gray remains a shareholder in Zelira. 공고 • May 22
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding Zelira Therapeutics Limited announced a private placement for the gross proceeds of $22 million on May 22, 2023. The company has raised $35 million in total funding till date. 공고 • Feb 20
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director Zelira Therapeutics Limited announced Mr. Greg Blake has been promoted from VP - Global Head of Commercial and Partnering to Executive Director effective 20 February 2023. Mr. Blake has been employed by Zelira since 2020. Greg brings extensive commercial and operational leadership experience in the pharmaceutical and biotech sectors both within Australia and internationally. Greg has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets. As Marketing Lead (Europe) with Mundipharma International, Greg successfully led 26 European countries through the pre-launch and launch phases for a novel pain medication.Greg has held leadership roles at large multinationals (J&J and CSL) and publicly-listed biotech start-ups. 
